Price
$0.4159
Decreased by -10.56%
Dollar Volume (20D)
1.87 M
ADR%
16.04
Earnings Report Date (estimate)
Mar 5, 24
Shares Float
25.98 M
Shares Outstanding
78.31 M
Shares Short
47.03 K
Market Cap.
35.42 M
Beta
1.78
Price / Earnings
N/A
20D Range
0.19 0.74
50D Range
0.19 0.74
200D Range
0.19 1.67
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Mar 5, 24 0
Increased by +100%
-0.21
Increased by +100%
Nov 9, 23 -0.18
Decreased by -123.68%
-0.19
Increased by +5.26%
Aug 10, 23 -0.16
Increased by +56.27%
-0.2
Increased by +20%
May 11, 23 -0.21
Decreased by -62.69%
-0.22
Increased by +3.86%
Mar 7, 23 -0.72
Decreased by -1.1 K%
-0.31
Decreased by -132.26%
Nov 10, 22 0.76
Increased by +7.7 K%
-0.25
Increased by +404%
Aug 12, 22 -0.37
Decreased by -3.56 K%
-
May 16, 22 -0.13 -
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 702 K
Increased by +756.1%
-15.88 M
Decreased by -112.08%
Decreased by -2.26 K%
Decreased by -101.41%
Jun 30, 23 114 K
Increased by +78.13%
-11.76 M
Increased by +47.63%
Decreased by -10.31 K%
Increased by +70.6%
Mar 31, 23 113 K
Increased by +71.21%
-22.93 M
Decreased by -4.96%
Decreased by -20.29 K%
Increased by +38.7%
Dec 31, 22 111 K
Decreased by -31.06%
-16.82 M
Increased by +14.26%
Decreased by -15.15 K%
Decreased by -24.37%
Sep 30, 22 82 K
Decreased by -47.1%
131.47 M
Increased by +824.89%
Increased by +160.33 K%
Increased by +1.47 K%
Jun 30, 22 64 K
Increased by +N/A%
-22.45 M
Decreased by -15.7 M%
Decreased by -35.08 K%
-
Mar 31, 22 66 K
Increased by +N/A%
-21.84 M
Decreased by N/A%
Decreased by -33.09 K%
-
Dec 31, 21 161 K
Increased by +61%
-19.61 M
Decreased by -157.23%
Decreased by -12.18 K%
Decreased by -59.77%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. Akili, Inc. was founded in 2011 and is headquartered in Boston, Massachusetts.